Reports FY24 revenue $33.279M vs $14.017M last year. “MeiraGTx (MGTX) demonstrated excellent execution in 2024, marked by significant ...

Holdings announced a broad strategic collaboration with Hologen. MeiraGTx will receive $200 million in upfront cash at closing ...

Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy PlatformsLONDON and NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq ...

MeiraGTx is advancing its investigational gene therapy toward expedited approval in the UK after 11 children who were born blind from birth gained significant vision improvements following treatment.

Credit: Tom Merton via Getty Images. MeiraGTx is advancing its investigational gene therapy toward expedited approval in the UK after 11 children who were born blind from birth gained significant ...

NEW YORK – MeiraGTx on Friday said it intends to submit a marketing authorization application (MAA) to the UK Medicines and Healthcare products Regulatory Authority (MHRA) for its investigational gene ...

Shares of MeiraGTx Holdings shares reached a 52-week high after the company said 11 children treated to date in a drug study gained visual acuity after treatment. The stock was recently up 9.1% ...

MeiraGTx (MGTX) stock rose 7% after publishing promising results from the first human trial using gene therapy to treat AIPL1-associated severe retinal dystrophy in children. Across all trials so ...

MeiraGTx Holdings plc announced promising results from a first-in-human study published in The Lancet, involving a gene therapy treatment for children with AIPL1-associated retinal dystrophy ...

Eleven children who were legally blind at birth all gained visual acuity after receiving MeiraGTx's investigational gene therapy, data that are prompting the biotech to seek accelerated approval ...

Gene therapy specialist Meiragtx Holdings plc is heading for its first marketing approval following the successful treatment of 11 children with Leber amaurosis, a severe form of congenital retinal ...

benefited substantially from treatment with Meiragtx Holdings plc’s rAAV8.hRKp.AIPL1 gene therapy. The four children were enrolled in the first clinical trial cohort, but a further seven children ...